Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 332

1.

Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization.

Huang RSP, Smith D, Le CH, Liu WW, Ordinario E, Manohar C, Lee M, Rajamani J, Truong H, Li J, Choi C, Li J, Pati A, Bubendorf L, Buettner R, Kerr KM, Lopez-Rios F, Marchetti A, Marondel I, Nicholson AG, Öz AB, Pauwels P, Penault-Llorca F, Rossi G, Thunnissen E, Newell AH, Pate G, Menzl I.

Arch Pathol Lab Med. 2019 Sep 11. doi: 10.5858/arpa.2019-0085-OA. [Epub ahead of print]

PMID:
31509456
2.

Comparison of in Situ and Extraction-Based Methods for the Detection of ROS1 Rearrangements in Solid Tumors.

Heydt C, Ruesseler V, Pappesch R, Wagener S, Haak A, Siebolts U, Riedel R, Michels S, Wolf J, Schultheis AM, Rehker J, Buettner R, Merkelbach-Bruse S.

J Mol Diagn. 2019 Aug 2. pii: S1525-1578(19)30349-6. doi: 10.1016/j.jmoldx.2019.06.006. [Epub ahead of print]

PMID:
31382035
3.

Leflunomide Synergizes with Gemcitabine in Growth Inhibition of PC Cells and Impairs c-Myc Signaling through PIM Kinase Targeting.

Buettner R, Morales C, Wu X, Sanchez JF, Li H, Melstrom LG, Rosen ST.

Mol Ther Oncolytics. 2019 May 17;14:149-158. doi: 10.1016/j.omto.2019.04.006. eCollection 2019 Sep 27.

4.

Increasing Antitumor Activity of JAK Inhibitor by Simultaneous Blocking Multiple Survival Signaling Pathways in Human Ovarian Cancer.

Wen W, Han ES, Dellinger TH, Wu J, Guo Y, Buettner R, Horne DA, Jove R, Yim JH.

Transl Oncol. 2019 Aug;12(8):1015-1025. doi: 10.1016/j.tranon.2019.05.003. Epub 2019 May 26.

5.

The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma.

Loeser H, Kraemer M, Gebauer F, Bruns C, Schröder W, Zander T, Persa OD, Alakus H, Hoelscher A, Buettner R, Lohneis P, Quaas A.

Oncoimmunology. 2019 Feb 27;8(5):e1581546. doi: 10.1080/2162402X.2019.1581546. eCollection 2019.

6.

Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva.

Thangarajah F, Morgenstern B, Pahmeyer C, Schiffmann LM, Puppe J, Mallmann P, Hamacher S, Buettner R, Alidousty C, Holz B, Scheel AH, Schultheis AM.

J Cancer Res Clin Oncol. 2019 Jun;145(6):1651-1660. doi: 10.1007/s00432-019-02915-1. Epub 2019 Apr 10.

PMID:
30972492
7.

Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy.

Klein S, Mauch C, Wagener-Ryczek S, Schoemmel M, Buettner R, Quaas A, Helbig D.

Cancer Immunol Immunother. 2019 Jun;68(6):973-982. doi: 10.1007/s00262-019-02339-3. Epub 2019 Apr 8.

PMID:
30963193
8.

Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting.

Buettner R, Morales C, Caserta E, Troadec E, Gunes EG, Viola D, Khalife J, Li H, Keats JJ, Christofferson A, Wu X, Synold TW, Palmer J, Sanchez JF, Pozhitkov A, Vaidehi N, Marcucci G, Krishnan A, Rosenzweig MA, Pichiorri F, Rosen ST.

Blood Adv. 2019 Apr 9;3(7):1027-1032. doi: 10.1182/bloodadvances.2018027227. No abstract available.

9.

Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology.

Alidousty C, Baar T, Heydt C, Wagener-Ryczek S, Kron A, Wolf J, Buettner R, Schultheis AM.

J Thorac Dis. 2019 Jan;11(Suppl 1):S3-S8. doi: 10.21037/jtd.2018.12.03. Review.

10.

8-chloro-adenosine activity in FLT3-ITD acute myeloid leukemia.

Buettner R, Nguyen LXT, Kumar B, Morales C, Liu C, Chen LS, Pemovska T, Synold TW, Palmer J, Thompson R, Li L, Hoang DH, Zhang B, Ghoda L, Kowolik C, Kontro M, Leitch C, Wennerberg K, Yu X, Chen CC, Horne D, Gandhi V, Pullarkat V, Marcucci G, Rosen ST.

J Cell Physiol. 2019 Feb 15. doi: 10.1002/jcp.28294. [Epub ahead of print]

PMID:
30770553
11.

LSD1 Inhibition Attenuates Tumor Growth by Disrupting PLK1 Mitotic Pathway.

Dalvi PS, Macheleidt IF, Lim SY, Meemboor S, Müller M, Eischeid-Scholz H, Schaefer SC, Buettner R, Klein S, Odenthal M.

Mol Cancer Res. 2019 Jun;17(6):1326-1337. doi: 10.1158/1541-7786.MCR-18-0971. Epub 2019 Feb 13.

PMID:
30760542
12.

Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.

Quaas A, Heydt C, Waldschmidt D, Alakus H, Zander T, Goeser T, Kasper P, Bruns C, Brunn A, Roth W, Hartmann N, Bunck A, Schmidt M, Buettner R, Merkelbach-Bruse S.

BMC Gastroenterol. 2019 Feb 4;19(1):21. doi: 10.1186/s12876-019-0942-z.

13.

Combined Targeted Resequencing of Cytosine DNA Methylation and Mutations of DNA Repair Genes with Potential Use for Poly(ADP-Ribose) Polymerase 1 Inhibitor Sensitivity Testing.

Grimm C, Fischer A, Farrelly AM, Kalachand R, Castiglione R, Wasserburger E, Hussong M, Schultheis AM, Altmüller J, Thiele H, Reinhardt HC, Hauschulz K, Hennessy BT, Herwig R, Lienhard M, Buettner R, Schweiger MR.

J Mol Diagn. 2019 Mar;21(2):198-213. doi: 10.1016/j.jmoldx.2018.10.007. Epub 2018 Dec 19.

PMID:
30576872
14.

Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies.

Castiglione R, Alidousty C, Holz B, Wagener S, Baar T, Heydt C, Binot E, Zupp S, Kron A, Wolf J, Merkelbach-Bruse S, Reinhardt HC, Buettner R, Schultheis AM.

Mod Pathol. 2019 May;32(5):627-638. doi: 10.1038/s41379-018-0182-8. Epub 2018 Nov 20.

15.

Author Correction: LSD1 modulates the non-canonical integrin β3 signaling pathway in non-small cell lung carcinoma cells.

Lim SY, Macheleidt I, Dalvi P, Schäfer SC, Kerick M, Ozretić L, Ortiz-Cuaran S, George J, Merkelbach-Bruse S, Wolf J, Timmermann B, Thomas RK, Schweiger MR, Buettner R, Odenthal M.

Sci Rep. 2018 Nov 1;8(1):16452. doi: 10.1038/s41598-018-31451-0.

16.

Genomic Characterization of TP53-Wild-Type Esophageal Carcinoma.

Quaas A, Heydt C, Gebauer F, Alakus H, Loeser H, Buettner R, Hillmer A, Bruns C, Merkelbach-Bruse S, Zander T, Frommolt P.

Transl Oncol. 2019 Jan;12(1):154-161. doi: 10.1016/j.tranon.2018.09.007. Epub 2018 Oct 11. No abstract available.

17.

Immunohistochemical expression of melanocytic and myofibroblastic markers and their molecular correlation in atypical fibroxanthomas and pleomorphic dermal sarcomas.

Helbig D, Mauch C, Buettner R, Quaas A.

J Cutan Pathol. 2018 Dec;45(12):880-885. doi: 10.1111/cup.13346. Epub 2018 Sep 27.

PMID:
30155964
18.

Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations.

Alidousty C, Baar T, Martelotto LG, Heydt C, Wagener S, Fassunke J, Duerbaum N, Scheel AH, Frank S, Holz B, Binot E, Kron A, Merkelbach-Bruse S, Ihle MA, Wolf J, Buettner R, Schultheis AM.

J Pathol. 2018 Sep;246(1):67-76. doi: 10.1002/path.5110. Epub 2018 Jul 31.

19.

Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel.

Quaas A, Waldschmidt D, Alakus H, Zander T, Heydt C, Goeser T, Daheim M, Kasper P, Plum P, Bruns C, Brunn A, Roth W, Hartmann N, Bunck A, Schmidt M, Göbel H, Tharun L, Buettner R, Merkelbach-Bruse S.

BMC Gastroenterol. 2018 May 31;18(1):75. doi: 10.1186/s12876-018-0803-1.

20.

Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer.

Meder L, Schuldt P, Thelen M, Schmitt A, Dietlein F, Klein S, Borchmann S, Wennhold K, Vlasic I, Oberbeck S, Riedel R, Florin A, Golfmann K, Schlößer HA, Odenthal M, Buettner R, Wolf J, Hallek M, Herling M, von Bergwelt-Baildon M, Reinhardt HC, Ullrich RT.

Cancer Res. 2018 Aug 1;78(15):4270-4281. doi: 10.1158/0008-5472.CAN-17-2176. Epub 2018 May 18.

21.

Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance.

Heydt C, Michels S, Thress KS, Bergner S, Wolf J, Buettner R.

Oncotarget. 2018 Mar 8;9(20):15418-15434. doi: 10.18632/oncotarget.24624. eCollection 2018 Mar 16. Review.

22.

Platelets promoting tumor metastasis: culprits or victims?

Buettner R.

J Thorac Dis. 2018 Feb;10(2):550-553. doi: 10.21037/jtd.2017.12.24. No abstract available.

23.

The landscape of genetic alterations in ameloblastomas relates to clinical features.

Gültekin SE, Aziz R, Heydt C, Sengüven B, Zöller J, Safi AF, Kreppel M, Buettner R.

Virchows Arch. 2018 May;472(5):807-814. doi: 10.1007/s00428-018-2305-5. Epub 2018 Feb 1.

24.

High protein and mRNA expression levels of TUBB3 (class III ß-tubulin) are associated with aggressive tumor features in esophageal adenocarcinomas.

Loeser H, Schallenberg S, von Winterfeld M, Tharun L, Alakus H, Hölscher A, Bollschweiler E, Buettner R, Zander T, Quaas A.

Oncotarget. 2017 Dec 11;8(70):115179-115189. doi: 10.18632/oncotarget.23112. eCollection 2017 Dec 29.

25.

Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma.

Caserta E, Chea J, Minnix M, Poku EK, Viola D, Vonderfecht S, Yazaki P, Crow D, Khalife J, Sanchez JF, Palmer JM, Hui S, Carlesso N, Keats J, Kim Y, Buettner R, Marcucci G, Rosen S, Shively J, Colcher D, Krishnan A, Pichiorri F.

Blood. 2018 Feb 15;131(7):741-745. doi: 10.1182/blood-2017-09-807263. Epub 2018 Jan 4. Erratum in: Blood. 2018 Jun 21;131(25):2869.

26.

PD-L1 expression in HNPCC-associated colorectal cancer.

Shiraliyeva N, Friedrichs J, Buettner R, Friedrichs N.

Pathol Res Pract. 2017 Dec;213(12):1552-1555. doi: 10.1016/j.prp.2017.09.012. Epub 2017 Sep 18.

PMID:
29033182
27.

Evolution analysis of heterogeneous non-small cell lung carcinoma by ultra-deep sequencing of the mitochondrial genome.

Amer W, Toth C, Vassella E, Meinrath J, Koitzsch U, Arens A, Huang J, Eischeid H, Adam A, Buettner R, Scheel A, Schaefer SC, Odenthal M.

Sci Rep. 2017 Sep 11;7(1):11069. doi: 10.1038/s41598-017-11345-3.

28.

LSD1 modulates the non-canonical integrin β3 signaling pathway in non-small cell lung carcinoma cells.

Lim SY, Macheleidt I, Dalvi P, Schäfer SC, Kerick M, Ozretić L, Ortiz-Cuaran S, George J, Merkelbach-Bruse S, Wolf J, Timmermann B, Thomas RK, Schweiger MR, Buettner R, Odenthal M.

Sci Rep. 2017 Aug 31;7(1):10292. doi: 10.1038/s41598-017-09554-x. Erratum in: Sci Rep. 2018 Nov 1;8(1):16452.

29.

Somatic BRCA1-associated protein 1 (BAP1) loss is an early and rare event in esophageal adenocarcinoma.

Loeser H, Waldschmidt D, Kuetting F, Schallenberg S, Zander T, Bollschweiler E, Hoelscher A, Weckermann K, Plum P, Alakus H, Buettner R, Quaas A.

Mol Clin Oncol. 2017 Aug;7(2):225-228. doi: 10.3892/mco.2017.1286. Epub 2017 Jun 8.

30.

Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia.

Knittel G, Rehkämper T, Korovkina D, Liedgens P, Fritz C, Torgovnick A, Al-Baldawi Y, Al-Maarri M, Cun Y, Fedorchenko O, Riabinska A, Beleggia F, Nguyen PH, Wunderlich FT, Ortmann M, Montesinos-Rongen M, Tausch E, Stilgenbauer S, P Frenzel L, Herling M, Herling C, Bahlo J, Hallek M, Peifer M, Buettner R, Persigehl T, Reinhardt HC.

Nat Commun. 2017 Jul 28;8(1):153. doi: 10.1038/s41467-017-00210-6.

31.

Lung cancer as a paradigm for precision oncology in solid tumours.

Schallenberg S, Merkelbach-Bruse S, Buettner R.

Virchows Arch. 2017 Aug;471(2):221-233. doi: 10.1007/s00428-017-2183-2. Epub 2017 Jul 20. Review.

PMID:
28730537
32.

Genomic and transcriptomic heterogeneity of colorectal tumours arising in Lynch syndrome.

Binder H, Hopp L, Schweiger MR, Hoffmann S, Jühling F, Kerick M, Timmermann B, Siebert S, Grimm C, Nersisyan L, Arakelyan A, Herberg M, Buske P, Loeffler-Wirth H, Rosolowski M, Engel C, Przybilla J, Peifer M, Friedrichs N, Moeslein G, Odenthal M, Hussong M, Peters S, Holzapfel S, Nattermann J, Hueneburg R, Schmiegel W, Royer-Pokora B, Aretz S, Kloth M, Kloor M, Buettner R, Galle J, Loeffler M.

J Pathol. 2017 Oct;243(2):242-254. doi: 10.1002/path.4948. Epub 2017 Sep 5.

PMID:
28727142
33.

Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.

Plenker D, Riedel M, Brägelmann J, Dammert MA, Chauhan R, Knowles PP, Lorenz C, Keul M, Bührmann M, Pagel O, Tischler V, Scheel AH, Schütte D, Song Y, Stark J, Mrugalla F, Alber Y, Richters A, Engel J, Leenders F, Heuckmann JM, Wolf J, Diebold J, Pall G, Peifer M, Aerts M, Gevaert K, Zahedi RP, Buettner R, Shokat KM, McDonald NQ, Kast SM, Gautschi O, Thomas RK, Sos ML.

Sci Transl Med. 2017 Jun 14;9(394). pii: eaah6144. doi: 10.1126/scitranslmed.aah6144.

34.

Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target.

Loeser H, Waldschmidt D, Kuetting F, Heydt C, Zander T, Plum P, Alakus H, Buettner R, Quaas A.

Mol Clin Oncol. 2017 May;6(5):639-642. doi: 10.3892/mco.2017.1194. Epub 2017 Mar 14.

35.

The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases.

Thunnissen E, Borczuk AC, Flieder DB, Witte B, Beasley MB, Chung JH, Dacic S, Lantuejoul S, Russell PA, den Bakker M, Botling J, Brambilla E, de Cuba E, Geisinger KR, Hiroshima K, Marchevsky AM, Minami Y, Moreira A, Nicholson AG, Yoshida A, Tsao MS, Warth A, Duhig E, Chen G, Matsuno Y, Travis WD, Butnor K, Cooper W, Mino-Kenudson M, Motoi N, Poleri C, Pelosi G, Kerr K, Aisner SC, Ishikawa Y, Buettner RH, Keino N, Yatabe Y, Noguchi M.

J Thorac Oncol. 2017 Feb;12(2):334-346. doi: 10.1016/j.jtho.2016.12.004. Epub 2016 Dec 18.

36.

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, Lim WT, LoRusso P, Shapiro GI, Parker K, Chen X, Choudhury S, Ringeisen F, Graus-Porta D, Porter D, Isaacs R, Buettner R, Wolf J.

J Clin Oncol. 2017 Jan 10;35(2):157-165. Epub 2016 Nov 21. Erratum in: J Clin Oncol. 2017 Mar 10;35(8):926. J Clin Oncol. 2019 Feb 1;37(4):358.

PMID:
27870574
37.

The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer.

Porres D, Pfister D, Thissen A, Kuru TH, Zugor V, Buettner R, Knuechel R, Verburg FA, Heidenreich A.

Prostate Cancer Prostatic Dis. 2017 Mar;20(1):85-92. doi: 10.1038/pcan.2016.54. Epub 2016 Nov 8.

PMID:
27824042
38.

HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat.

Angelika Ihle M, Merkelbach-Bruse S, Hartmann W, Bauer S, Ratner N, Sonobe H, Nishio J, Larsson O, Åman P, Pedeutour F, Taguchi T, Wardelmann E, Buettner R, Schildhaus HU.

J Pathol Clin Res. 2016 Feb 5;2(2):59-71. doi: 10.1002/cjp2.35. eCollection 2016 Apr.

39.

Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.

Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T, Reu S, Rüschoff J, Schildhaus HU, Schirmacher P, Tiemann M, Warth A, Weichert W, Fischer RN, Wolf J, Buettner R.

Mod Pathol. 2016 Oct;29(10):1165-72. doi: 10.1038/modpathol.2016.117. Epub 2016 Jul 8.

40.

Unusual Presentation of an Adenocarcinoma of the Lung Metastasizing to the Mandible, Including Molecular Analysis and a Review of the Literature.

Gultekin SE, Senguven B, Isik Gonul I, Okur B, Buettner R.

J Oral Maxillofac Surg. 2016 Oct;74(10):2007.e1-8. doi: 10.1016/j.joms.2016.06.004. Epub 2016 Jun 12. Review.

PMID:
27376181
41.

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.

Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen L, Scheel AH, Fernandez-Cuesta L, Meder L, Lovly CM, Persigehl T, Merkelbach-Bruse S, Bos M, Michels S, Fischer R, Albus K, König K, Schildhaus HU, Fassunke J, Ihle MA, Pasternack H, Heydt C, Becker C, Altmüller J, Ji H, Müller C, Florin A, Heuckmann JM, Nuernberg P, Ansén S, Heukamp LC, Berg J, Pao W, Peifer M, Buettner R, Wolf J, Thomas RK, Sos ML.

Clin Cancer Res. 2016 Oct 1;22(19):4837-4847. Epub 2016 Jun 1.

42.

Prediction of outcome by lymph node ratio in patients with parotid gland cancer.

Meyer MF, Kreppel M, Meinrath J, Grünewald I, Stenner M, Drebber U, Quaas A, Odenthal M, Semrau R, Huebbers CU, Zöller J, Huettenbrink KB, Buettner R, Beutner D.

Clin Otolaryngol. 2017 Feb;42(1):98-103. doi: 10.1111/coa.12672. Epub 2016 May 30.

PMID:
27185037
43.

Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.

Zhang Q, Hossain DM, Duttagupta P, Moreira D, Zhao X, Won H, Buettner R, Nechaev S, Majka M, Zhang B, Cai Q, Swiderski P, Kuo YH, Forman S, Marcucci G, Kortylewski M.

Blood. 2016 Mar 31;127(13):1687-700. doi: 10.1182/blood-2015-08-665604. Epub 2016 Jan 21.

44.

FGFR1 amplification and co-overexpression of c-MYC in oropharyngeal squamous cell carcinoma.

Ozretić L, Wagner S, Huebbers CU, Gattenlöhner S, Klussmann JP, Beutner D, Zander T, Buettner R, Quaas A.

Oral Oncol. 2016 Mar;54:e7-9. doi: 10.1016/j.oraloncology.2015.12.006. Epub 2016 Jan 8. No abstract available.

PMID:
26778475
45.

Allosteric Communication across STAT3 Domains Associated with STAT3 Function and Disease-Causing Mutation.

Namanja AT, Wang J, Buettner R, Colson L, Chen Y.

J Mol Biol. 2016 Feb 13;428(3):579-589. doi: 10.1016/j.jmb.2016.01.003. Epub 2016 Jan 14.

46.

Expression of the apoptosis repressor with caspase recruitment domain (ARC) in liver metastasis of colorectal cancer and its correlation with DNA mismatch repair proteins and p53.

Tóth C, Meinrath J, Herpel E, Derix J, Fries J, Buettner R, Schirmacher P, Heikaus S.

J Cancer Res Clin Oncol. 2016 May;142(5):927-35. doi: 10.1007/s00432-015-2102-3. Epub 2015 Dec 31.

PMID:
26721253
47.

Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases.

Meder L, König K, Fassunke J, Ozretić L, Wolf J, Merkelbach-Bruse S, Heukamp LC, Buettner R.

Exp Mol Pathol. 2015 Dec;99(3):682-6. doi: 10.1016/j.yexmp.2015.11.002. Epub 2015 Nov 10.

PMID:
26546837
48.

A sustained high fat diet for two years decreases IgM and IL-1 beta in ageing Wistar rats.

Pongratz G, Lowin T, Kob R, Buettner R, Bertsch T, Bollheimer LC.

Immun Ageing. 2015 Sep 28;12:12. doi: 10.1186/s12979-015-0040-1. eCollection 2015.

49.

NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.

Meder L, König K, Ozretić L, Schultheis AM, Ueckeroth F, Ade CP, Albus K, Boehm D, Rommerscheidt-Fuss U, Florin A, Buhl T, Hartmann W, Wolf J, Merkelbach-Bruse S, Eilers M, Perner S, Heukamp LC, Buettner R.

Int J Cancer. 2016 Feb 15;138(4):927-38. doi: 10.1002/ijc.29835. Epub 2015 Sep 25.

50.

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.

König K, Peifer M, Fassunke J, Ihle MA, Künstlinger H, Heydt C, Stamm K, Ueckeroth F, Vollbrecht C, Bos M, Gardizi M, Scheffler M, Nogova L, Leenders F, Albus K, Meder L, Becker K, Florin A, Rommerscheidt-Fuss U, Altmüller J, Kloth M, Nürnberg P, Henkel T, Bikár SE, Sos ML, Geese WJ, Strauss L, Ko YD, Gerigk U, Odenthal M, Zander T, Wolf J, Merkelbach-Bruse S, Buettner R, Heukamp LC.

J Thorac Oncol. 2015 Jul;10(7):1049-57. doi: 10.1097/JTO.0000000000000570.

Supplemental Content

Loading ...
Support Center